Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology

Drug Class Overviews revamped to address the changing needs of health care professionals

Tampa, FL, August 22, 2012 – Leading drug information provider Elsevier / Gold Standard announced today its new Drug Class Overviews, making Clinical Pharmacology more valuable at the point of care.

Clinical Pharmacology Drug Class Overviews are now even more powerful for evaluating formulary decisions and therapeutic drug substitutions. Elsevier / Gold Standard has improved the speed and usability of the content through bulleted summaries and tables, highlighting a variety of critical areas in drug-interaction information.

“The new Drug Class Overviews represent a significant evolution in our content development that was stimulated and driven by input from our clients,” said Elsevier / Gold Standard President Marianne Messer. “This advancement also represents the way in which our users wish to utilize our vast amount of drug information that is updated in real-time.”

The new Drug Class Overviews includes:

“Clinical Pharmacology has been named by independent research studies as the most complete and dependable drug reference solution on the market today. It is trusted by thousands of hospitals, 35,000 retail pharmacies, health plans, pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and academic institutions,” Messer said. “We are pleased to continue developing our solutions and meeting the needs of our users.”

For more information about Clinical Pharmacology and the new Drug Class Overviews, please visit www.goldstandard.com

# # #
About Elsevier / Gold Standard
Based in Tampa, FL, Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier / Gold Standard, visit www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Chris Capot
Director, Corporate Relations, Elsevier
+1 212 633 3164
c.capot@elsevier.com